Abbott seeks appeal on royalties to UK's Cambridge
Tuesday, 15 February, 2005
Abbott Laboratories is seeking to appeal a British court ruling that granted Cambridge Antibody Technology a greater percentage of royalties on Abbott's arthritis drug Humira.
In December, UK Judge Hugh Laddie said Abbott should pay Cambridge a royalty of just over 5 per cent on sales of Humira, compared with the royalty of 2 per cent of net sales it has been paying.
The application will be considered by one Court of Appeal judge, Cambridge said in a statement. If the application is unsuccessful, Abbott will be entitled to request a hearing.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
